Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exherin (ADH-1) in N-Cadherin Expressing Solid Tumors
NCT00265057Phase 2Completed
- Sponsor
- Adherex Technologies
- Start
- Jun 2005
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of ADH-1 in solid tumor, non-small cell lung cancer (NSCLC) and ovarian cancer, sponsored by Adherex Technologies. Primary endpoints: Maximum Tolerated Dose and Safety and Tolerability. Started Jun 2005; status: completed.
02
Drugs
ADH-1
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)ovarian cancer
Beyond the preview
Go deeper on NCT00265057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00265057.